Try our beta test site

A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2015 by Seoul National University Hospital
Information provided by (Responsible Party):
Seoul National University Hospital Identifier:
First received: February 21, 2013
Last updated: November 17, 2015
Last verified: November 2015
Activated T cell were manufactured through in vitro T cell expansion of autologous T cell. We designed this study to determine the feasibility and safety of Activated T-lymphocyte cell therapy for refractory/relapsed neuroblastoma patients.

Condition Intervention
Biological: Activated T lymphocyte

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma

Resource links provided by NLM:

Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • T cell count after in vitro expansion [ Time Frame: up to 13 weeks ]

    T cell count after in vitro expansion

    Evaluation of safety

Secondary Outcome Measures:
  • Number of participants who showed response with Response Evaluation Criteria in Solid Tumors criteria [ Time Frame: up to 1 year ]

    To determine the response rate

    To evaluate 1 yr progression free survival and overall survival

Estimated Enrollment: 6
Study Start Date: February 2013
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Activated T-lymphocyte

This was designed as a single-center, single group clinical trial, and subjects include patients with refractory refractory/relapsed neuroblastoma.

If subjects agree to participate in the clinical trial by signing a written consent, only appropriate subjects, who meet the criteria on the examinations and tests, will undergo this clinical trial. To participate in the clinical trial, subject's blood of more than 60 ml should be withdrawn to make a study drug at least 3 weeks before administration. Subjects should visit to hospital according to the protocol and receive a study drug. Therapeutic response rate, overall survival rate, time to progression should be investigated.

Biological: Activated T lymphocyte
intravenous dripping of 200 ml (10^9~2*10^10 lymphocytes) for 1 hour.
Other Name: Immuncell-LC


Ages Eligible for Study:   up to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Informed consent
  • Age 21 years or younger
  • Histologically confirmed neuroblastoma
  • Progressive disease after standard treatment or relapsed patient
  • ECOG scale (ECOG-PS) ≤2
  • Expected survival at least 3 months

Exclusion Criteria:

  • Patients with autoimmune disease
  • Patients with immunodeficiency
  • Other malignancy 5 year prior to this study
  • Severe organ dysfunction
  • Severe allergic disease
  • Severe psychiatric disorder
  • Pregnancy or lactating woman
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01802138

Contact: Hyoung Jin Kang, MD, Ph.D 82 2 2072 3304
Contact: Ji Won Lee, MD 82 2 2072 4192

Korea, Republic of
Seoul National University Hospital Recruiting
Seoul, Chongno-gu, Korea, Republic of
Contact: Hyoung Jin Kang, MD, Ph.D    82 2 2072 3304   
Principal Investigator: Hee Young Shin, MD, Ph.D         
Sponsors and Collaborators
Seoul National University Hospital
  More Information

Responsible Party: Seoul National University Hospital Identifier: NCT01802138     History of Changes
Other Study ID Numbers: ILC_IIT_03
Study First Received: February 21, 2013
Last Updated: November 17, 2015

Keywords provided by Seoul National University Hospital:
refractory/relapsed neuroblastoma patients

Additional relevant MeSH terms:
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue processed this record on March 30, 2017